

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email editorial.bmjopen@bmj.com

BMJ Open

Sepsis and Critical Illness Research Center Investigators: standard operating procedures for a prospective cohort study of sepsis in critically ill surgical patients

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-015136
Article Type:	Protocol
Date Submitted by the Author:	10-Nov-2016
Complete List of Authors:	Loftus, Tyler; Department of Surgery Mira, Juan; Department of Surgery Ozrazgat-Baslanti, Tezcan; Department of Anesthesiology Stortz, Julie; Department of Surgery Brumback, Babette ; Department of Biostatistics Bihorac, Azra; Department of Anesthesiology Segal, Mark; Department of Medicine Anton, Stephen; Institute on Aging Leeuwenburgh, Christiaan; Institute on Aging Mohr, Alicia; Department of Surgery Efron, Philip; Department of Surgery Moldawer, Lyle; Department of Surgery Moore, Frederick; Department of Surgery Brakenridge, Scott; University of Florida, General Surgery
Primary Subject Heading:	Intensive care
Secondary Subject Heading:	Epidemiology, Evidence based practice, Health informatics, Research methods, Surgery
Keywords:	Immunology < BASIC SCIENCES, Health informatics < BIOTECHNOLOGY & BIOINFORMATICS, Adult intensive & critical care < INTENSIVE & CRITICAL CARE, Adult surgery < SURGERY, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, CLINICAL PHYSIOLOGY

SCHOLARONE™
Manuscripts

**Sepsis and Critical Illness Research Center Investigators: standard operating procedures
for a prospective cohort study of sepsis in critically ill surgical patients**

Short title: SCIRC standard operating procedures

Tyler J. Loftus, MD^{a,b} (Tyler.Loftus@surgery.ufl.edu)

Juan C. Mira, MD^{a,b} (Juan.Mira@surgery.ufl.edu)

Tezcan Ozrazgat-Baslanti, PhD^{a,c} (Tezcan.OzrazgatBaslanti@medicine.ufl.edu)

Julie A. Stortz, MD^{a,b} (Julie.Stortz@surgery.ufl.edu)

Babette A. Brumback, PhD^{a,d} (brumback@PHHP.ufl.edu)

Azra Bihorac, MD^{a,c} (abihorac@anest.ufl.edu)

Mark S. Segal, MD, PhD^{a,e} (Mark.Segal@medicine.ufl.edu)

Stephen D. Anton, PhD^{a,f} (santon@ufl.edu)

Christiaan Leeuwenburgh, PhD^{a,f} (cleeuwen@ufl.edu)

Alicia M. Mohr, MD^{a,b} (Alicia.Mohr@surgery.ufl.edu)

Philip A. Efron MD^{a,b} (Philip.Efron@surgery.ufl.edu)

Lyle L. Moldawer, PhD^{a,b} (Lyle.Moldawer@surgery.ufl.edu)

Frederick A. Moore MD^{a,b} (Frederick.Moore@surgery.ufl.edu)

Scott C. Brakenridge, MD, MSCS^{a,b} (Scott.Brakenridge@surgery.ufl.edu)

^aUniversity of Florida Health, Department of Surgery and Sepsis and Critical Illness Research Center in Gainesville, Florida

^bUniversity of Florida Health, Department of Surgery

^cUniversity of Florida Health, Department of Anesthesiology

^dUniversity of Florida Health, Department of Biostatistics

^eUniversity of Florida Health, Department of Medicine

^fUniversity of Florida Health, Institute on Aging

Please address correspondence to:

Scott C. Brakenridge MD, MSCS

University of Florida Health, Gainesville, FL

1600 SW Archer Road Room M-602

Gainesville, FL, 32610-3003

972-415-2447

Scott.Brakenridge@surgery.ufl.edu

The authors have no relevant conflicts of interest. The authors were supported by P50 GM111152–01 awarded by the National Institute of General Medical Sciences (NIGMS). TJL was supported by a post-graduate training grant (T32 GM-08721) in burns, trauma and perioperative injury from the NIGMS.

Abstract

Introduction: Sepsis is a common, costly, and morbid cause of critical illness in trauma and surgical patients. Ongoing advances in sepsis resuscitation and critical care support strategies have led to improved in-hospital mortality. However, these patients now survive to a enter state of chronic critical illness (CCI), persistent low-grade organ dysfunction, and poor long-term outcomes driven by the persistent inflammation, immunosuppression, and catabolism syndrome (PICS). The Sepsis and Critical Illness Research Center (SCIRC) was created to provide a platform by which the prevalence and pathogenesis of CCI and PICS may be understood at a mechanistic level across multiple medical disciplines, leading to the development of novel management strategies and targeted therapies.

Methods: Here we describe the design, study cohort, and standard operating procedures used in the prospective study of human sepsis at a level 1 trauma center and tertiary care hospital providing care for over 2,600 critically ill patients annually. These procedures include implementation of an automated sepsis surveillance initiative, augmentation of clinical decisions with a computerized sepsis protocol, strategies for direct exportation of quality-filtered data from the electronic medical record to a research database, and robust long-term follow-up.

Ethics and dissemination: This study has been registered at Clinicaltrials.gov and is actively enrolling subjects. Dissemination of preliminary results is forthcoming.

Strengths and limitations of this study

- Computerized decision support will minimize the influence of variability in management practices
- Robust long-term follow-up will allow for deeper understanding of functional recovery following sepsis
- Investigation of targeted therapies is currently limited by deficiencies our understanding of sepsis pathophysiology

Introduction

Sepsis as both a cause and complication of surgical intensive care unit admission is common, costly, and morbid. Hospitalization with sepsis has become more common than hospitalization with myocardial infarction, with annual costs over \$20 billion in the United States^{1,2}. Mortality rates for sepsis range from 18-28%, and remain unacceptably high despite more than 30 years of intensive research^{3,4}. Recent advances in resuscitation strategies have improved in-hospital mortality, but sepsis survivors often enter a state of chronic critical illness (CCI) driven by the persistent inflammation, immunosuppression, and catabolism syndrome (PICS)^{5,6} (Figure 1). However, the pathophysiology of these conditions remains incompletely understood. The Sepsis and Critical Illness Research Center (SCIRC) was created to provide a platform by which the prevalence and pathogenesis of PICS may be understood at a mechanistic level across multiple medical disciplines, leading to the development of novel management strategies and targeted therapies.

Methods and analysis

Setting

The University of Florida Health Shands Hospital (Gainesville, Florida; U.S.A.) is a Level 1 Trauma and tertiary care center with two trauma/surgical intensive care units (ICU) totaling 48 beds, which serve as the recruitment base for this cohort study. UF Health is the sole tertiary care center for a greater than 90-mile radius catchment area, including over 1.5 million

1
2
3 people. Together, the trauma and surgical ICU teams manage over 2,600 critically ill patients
4
5 annually. Each ICU has a dedicated surgical critical care team including a board certified
6
7 attending intensivist, critical care fellows, surgical and anesthesia residents, and advanced
8
9 practice providers (physician assistants and nurse practitioners). These teams collaborate with
10
11 unit-dedicated pharmacists, respiratory therapists, physical therapists, occupational therapists,
12
13 nutritionists, and social workers. Board certified attending acute care surgeons and critical care
14
15 fellows provide in-hospital coverage 24 hours per day, 7 days per week.
16
17
18
19
20
21
22
23

24 Study design and population

25
26
27 This is a prospective, longitudinal cohort study of surgical intensive care unit (ICU)
28
29 patients that develop surgical sepsis. Based on preliminary data and *a priori* power analyses,
30
31 400 patients will be enrolled over a period of 4 years, with subsequent 12-month individual
32
33 follow-up. Inclusion criteria are presence in the trauma/surgical intensive care unit, age ≥ 18
34
35 years, and diagnosis with sepsis, severe sepsis or septic shock with subsequent initiation of the
36
37 computerized clinical decision support (CCDS) directed sepsis protocol ^{7,8}. Septic patients are
38
39 initially identified by a modified version of the Modified Early Warning Score (MEWS-SRS) ⁹,
40
41 which screens for sepsis based on temperature, heart rate, respiratory rate, blood pressure, and
42
43 level of consciousness (Figure 2). In the emergency department and on surgical wards, this score
44
45 is calculated for each patient on arrival, every time vital signs are recorded, and any time a
46
47 patient has an acute change from their baseline physiologic status, prompting further
48
49 investigation. Patients identified by the MEWS screening protocol are then directly assessed by
50
51 a physician or advance practice provider for bedside clinical adjudication of the presence of
52
53
54
55
56
57
58
59
60

1
2
3 sepsis (a systemic inflammatory response with a source of infection), severe sepsis (sepsis-
4 induced tissue hypoperfusion or organ dysfunction), or septic shock (severe sepsis with
5
6 induced tissue hypoperfusion or organ dysfunction), or septic shock (severe sepsis with
7
8 persistent arterial hypotension despite volume resuscitation) based on consensus definitions¹⁰⁻¹³.
9

10 This screening and diagnostic process has been automated and embedded within the UF Health
11
12 electronic medical record (Epic Systems, Verona, WI).
13

14
15
16 Exclusion criteria are age <18 years, severe traumatic brain injury (i.e. CT evidence of
17
18 neurologic injury and Glasgow Coma Scale score <8), spinal cord injury resulting in permanent
19
20 sensory and/or motor deficits, sepsis with an uncontrollable source (e.g. unresectable bowel
21
22 ischemia), NY Heart Association class IV heart failure, Child-Pugh Class B or C liver disease,
23
24 known HIV infection with CD4 count <200 cells/mm³, organ transplant recipient on an
25
26 immunosuppressant agent, chemotherapy or radiotherapy within 30 days prior to onset of sepsis,
27
28 expected lifespan <3 months due to severe pre-existing comorbidities, active Do Not Resuscitate
29
30 or Do Not Intubate order, pregnancy, incarceration, or institutionalization.
31
32
33
34
35
36
37
38

39 Computerized clinical decision support (CCDS) sepsis protocol

40
41
42 Patients who are diagnosed with sepsis, severe sepsis, or septic shock are started on a
43
44 computerized clinical decision support protocol, as previously described⁷. This system was
45
46 modified from a sepsis management protocol originally implemented at the Methodist Hospital
47
48 in Houston, Texas⁸. In brief, mobile bedside computer workstations were programed with
49
50 sepsis protocol algorithm logic that interacts with the patient and clinician by mapping clinical
51
52 workflow and recommendations to patient physiology and clinical interventions. The sepsis
53
54 protocol algorithm logic was developed by a multidisciplinary team of surgeons, intensivists,
55
56
57
58
59
60

1
2
3 advanced practitioners, nurses, respiratory therapists, pharmacists, pathologists, and computer
4
5 engineers, based on Surviving Sepsis Campaign guidelines¹³. The algorithm produces a
6
7 recommendation; the clinician may accept or modify the recommendation, tailoring care to
8
9 individual patient-specific factors. The selected intervention is then imputed, and the
10
11 computerized clinical workflow and recommendations continue to evolve.
12
13

14
15
16 The computerized sepsis protocol is the platform for clinical decisions regarding initial
17
18 volume resuscitation and antibiotic therapy initiation. For all other clinical decisions, the SCIRC
19
20 developed protocols based on standard operating procedures from the Inflammation and the Host
21
22 Response to Injury Collaborative Research Program¹⁴⁻²³. SCIRC protocols include a traumatic
23
24 brain injury management protocol, sedation and analgesia protocol, delirium protocol,
25
26 mechanical ventilation protocol, ventilator associated pneumonia prevention bundle, blood
27
28 product transfusion protocol, nutritional support protocol, stress ulcer prophylaxis protocol,
29
30 electrolyte replacement protocol, subcutaneous and continuous infusion insulin protocol, venous
31
32 thromboembolism prophylaxis protocol, and progressive upright mobility protocol.
33
34
35
36
37
38

39 Subject recruitment

40
41
42 When a patient diagnosed with sepsis, a page notification is sent to a team of research
43
44 nurses who respond to evaluate for study enrollment 24 hours per day, 7 days per week. The
45
46 research nurse on-call evaluates inclusion and exclusion criteria. If the patient qualifies, the
47
48 research nurse seeks to obtain informed consent from the patient (if able) or legally authorized
49
50 representative. Similar to the Inflammation and Host Response to Injury program, a 96-hour
51
52 waiver of informed consent exists for initial sample and data collection based upon previous
53
54 precedent at this institution, and approved by the institutional review board (IRB)¹⁴⁻¹⁶. If
55
56
57
58
59
60

1
2
3 consent is not able to be obtained after 96 hours, all initial blood samples and patient data are
4 destroyed. If consent is initially obtained from the legally authorized representative and the
5
6 patient regains decision-making capacity, the patient has the opportunity to withdraw from the
7
8 study at that time. Study subjects may choose to participate during hospital admission with or
9
10 without long-term follow-up, though long-term follow-up is encouraged, per study objectives.
11
12
13

14
15
16 Within the first seven days, all study subjects undergo prospective clinical adjudication to
17
18 confirm proper diagnosis, source identification, and severity classification of sepsis during
19
20 weekly SCIRC adjudication and retention committee meetings. As this study was designed and
21
22 initiated prior to the Sepsis-3 consensus statement, sepsis severity is classified by previously
23
24 established consensus definitions¹⁰⁻¹³. However, data collected during the course of the study
25
26 will allow for subsequent classification and comparison to the subsequently released Sepsis-3
27
28 consensus statement²⁴.
29
30
31
32
33
34
35
36

37 Data procurement and management

38
39
40 Data describing baseline characteristics, management, and outcomes for each study
41
42 subject are prospectively collected, recorded, and managed using the REDCapTM (REDCap
43
44 consortium; www.projectredcap.org) research electronic case report form platform²⁵. In
45
46 collaboration with the University of Florida Clinical and Translational Science Institute (CTSI),
47
48 our center developed an automated data collection and integration system that extracts clinical
49
50 data from the electronic medical record and uploads the data to REDCap over a secure server on
51
52 a daily basis. Raw data from the electronic medical record (EMR), including information on
53
54 patient laboratory results, vital signs, medications, and information related to hospital and ICU
55
56
57
58
59
60

1
2
3 admission and discharge are directly uploaded to the SCIRC database by the University of
4
5 Florida Health Integrated Data Repository (IDR). The SCIRC database includes over 800 data
6
7 fields describing the vital signs, clinical signs and symptoms of sepsis, medical history,
8
9 laboratory values, microbiologic analyses, cardiopulmonary resuscitation parameters, procedural
10
11 interventions, medications, infusions, and outcomes for each patient. Parameters available in the
12
13 EMR are transferred to the SCIRC database after compilation and quality filtering via the IDR
14
15 system. Data from biologic sampling analyses performed by the Bioanalytical Core (e.g. flow
16
17 cytometry, ELISA, multiplex, and gene analyses) are also transferred to the SCIRC drive as they
18
19 are completed. The SCIRC database gives each project access to its own protected folder and to
20
21 a bridge folder in which data can be placed for transfer to the Database Management and
22
23 Biostatistics Core personnel for quality control and statistical analyses. The quality and accuracy
24
25 of the transferred data is validated at regular intervals by the Database Management and
26
27 Biostatistics Core. Parameters that are not available in the electronic medical record are
28
29 manually extracted and entered into the REDCap case report form platform. Data regarding the
30
31 inpatient hospital course prior to protocol initiation are also collected. For patients transferred
32
33 from another facility, this includes records from the outside facility regarding the initial signs
34
35 and symptoms of sepsis, microbiologic findings, antibiotic administration parameters, and source
36
37 control procedures.
38
39
40
41
42
43
44
45
46
47
48
49

50 Biomarker sampling, processing, and analysis

51
52

53 Tissue samples are collected at scheduled intervals for biomarkers analyses of
54
55 inflammation (e.g. plasma tumor necrosis factor-alpha, interleukin (IL)-1, IL-2, IL-3, IL-5, IL-6,
56
57
58
59
60

1
2
3 IL-10, IL-12, interferon-gamma, macrophage inflammatory protein 1-alpha),
4
5 immunosuppression (e.g. granulocytic and monocytic myeloid-derived suppressor cells in whole
6
7 blood) and catabolism (e.g. serum prealbumin, urine 3-methylhistidine, skeletal muscle high-
8
9 resolution respirometry *in situ*) from 12 hours out to 42 days or inpatient discharge. For
10
11 purposes of sample collection, time zero coincides with initiation of the sepsis protocol. Blood
12
13 samples and laboratory measurements are obtained at the following time points, relative to sepsis
14
15 protocol and study initiation: 12 hours, 1 day, 4 days, 7 days, 14 days, 21 days, 28 days, 35 days,
16
17 and 42 days. Initial sample processing, including centrifugation, labeling, and freezing of
18
19 patient samples, is performed 24 hours per day, 7 days per week at an on-site sample processing
20
21 laboratory located within the trauma ICU. All samples are subsequently transported to the
22
23 Bioanalytics core or individual project laboratories as appropriate. Analytic methods include
24
25 flow cytometry, enzyme-linked immunosorbent assay, multiplex, and gene expression array
26
27 (NanoString Technologies, Seattle, WA, and Affymetrix, Cleveland, OH). The analytic plan
28
29 followed the STROBE recommendations for observational cohort studies²⁶.
30
31
32
33
34
35
36
37
38
39
40

41 Subject retention, clinical assessments, and long-term follow-up

42
43
44 During the index hospitalization, clinical assessments focus on host factors (e.g. age,
45
46 gender, comorbidities, hospital course prior to ICU admission), infection characteristics (e.g.
47
48 presumed type of infection, microbiologic data, antibiotic therapy), sepsis severity (e.g.
49
50 hemodynamic parameters, vasopressor support, laboratory measures of hypoxemia and tissue
51
52 ischemia, Sequential Organ Failure Assessment (SOFA) scores²⁷, APACHE II scores²⁸),
53
54 volume status by protocolized bedside echocardiography, procedural interventions to obtain
55
56
57
58
59
60

1
2
3 source control, nutritional parameters (e.g. caloric and protein goals, nitrogen balance, metabolic
4 cart for energy expenditure), and short-term outcomes (e.g. infectious complications, non-
5 infectious complications, ICU length of stay, days on mechanical ventilation, change in SOFA
6 score over time, in-hospital mortality, discharge disposition).
7
8
9
10
11

12
13
14 A retention committee creates an individualized follow-up plan for each study subject
15 prior to discharge from the hospital. The retention committee meets twice per week to discuss
16 all active study subjects, with special attention to subjects for whom long-term follow-up may be
17 jeopardized by geographic and social impediments. Phone contact encounters are scheduled and
18 used to predict retention problems. Parking and transportation costs are provided to the study
19 subjects to maximize access to the research center. Members of the retention committee are
20 trained to recognize and address psychosocial issues and provide emotional support as needed.
21 When medical and/or mental health problems necessitating further treatment are identified, the
22 retention committee provides referrals to the appropriate specialists, and ensures that care is
23 provided in a timely fashion.
24
25
26
27
28
29
30
31
32
33
34
35
36
37

38 Long-term follow-up outpatient clinic visits occur at 3 months, 6 months, and 12 months
39 at the facilities of the University of Florida Institute on Aging. Clinical assessments at these time
40 points will focus on functional recovery from sepsis by performing a battery of tests including
41 the Rand 36 Item SF health Survey²⁹, Mini Nutritional Assessment³⁰, EQ-5D-3L Health
42 Questionnaire³¹, Hopkins Verbal Learning Test³², Controlled Oral Word Association test³³,
43 Modified Mini-Mental State Exam³⁴, ECOG/WHO/Zubrod score³⁵, Short Physical Performance
44 Battery³⁶, hand grip strength measurement, and body composition measurements with the BIA
45 450 bioimpedance analyzer (Biodynamics Corporation, Shoreline, WA). If patients are
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 unwilling or unable to return for outpatient clinical follow-up, home-visits are scheduled (up to
4
5 2-hour drive radius), or subjective data is collected via telephone interview.
6
7

8
9 To identify and evaluate the progression of sarcopenia, we will perform computed
10
11 tomography (CT) morphometric assessments of psoas and abdominal wall lean muscle mass at
12
13 baseline, 3 months, and 12 months, using SliceOmatic software (version 5.0 rev 6a; Tomovision,
14
15 Magog, Quebec, Canada). Standard of care CT scans of the abdomen and pelvis conducted for
16
17 diagnostic purposes while the patient was hospitalized were used for this analysis. Two of these
18
19 CT scans were used: the baseline scan was performed within three days of sepsis protocol onset;
20
21 the second scan was performed within seven to fourteen days of the baseline scan. To calculate
22
23 the total skeletal muscle cross-sectional area (cm²), trained investigators identified and quantified
24
25 all skeletal muscles (psoas, paraspinal, and abdominal wall muscles) at the level of the third
26
27 lumbar (L3) vertebra where both transverse processes were visualized using established
28
29 Hounsfield unit (-29 to 150) attenuation thresholds for skeletal muscle tissue³⁷. The L3
30
31 vertebral level was chosen because skeletal muscle visualized at this axial plane has been shown
32
33 to correlate with whole-body muscle mass³⁸. Skeletal muscle index (SMI, cm²/m²) was then
34
35 calculated by normalizing the total skeletal muscle cross-sectional area (cm²) to patient height
36
37 squared (m²). Psoas muscle index (PMI, cm²/m²) was also calculated by normalizing only the
38
39 psoas muscle cross-sectional area (cm²) to patient height squared (m²).
40
41
42
43
44
45
46
47
48
49
50

51 Outcome definitions and analytic design

52

53
54 The primary outcomes of interest are the development of chronic critical illness (CCI)
55
56 and 1-year mortality rates after the development of sepsis. CCI is defined as an extended course
57
58
59
60

1
2
3 of critical illness with persistent organ dysfunction requiring intensive care resources. Extended
4
5 course of illness requiring intensive care resources is defined as total ICU days >14 days or being
6
7 discharged to another hospital, long term acute care hospital, or hospice. Persistent organ
8
9 dysfunction is defined as having a SOFA score of at least 2 in any organ system with the
10
11 exception of at least 1 for cardiovascular system on day 14 in ICU after protocol onset or last
12
13 SOFA score available, whichever comes first. Subjects are deemed to have developed CCI if
14
15 they are discharged to dispositions associated with poor outcomes (e.g. long term acute care
16
17 facility, skilled nursing facility) prior to ICU day 14 with ongoing evidence of organ dysfunction,
18
19 as described above. Mortality at 1-year will be determined by prospective follow-up, or from the
20
21 United States Social Security Death Index for those lost to follow-up.
22
23
24
25
26
27

28 Secondary outcomes of interest include changes in health, function and quality of life
29
30 assessments at 1-year after sepsis onset. Analyses will include the development of biomarker
31
32 and clinical prediction models for the development of CCI, as well as prediction models and the
33
34 development of a “CCI score” at ICU day 14 to predict 1-year mortality and poor functional
35
36 outcomes. Additionally, biomarker analyses at day 14 will seek to characterize the presence of
37
38 persistent inflammation, immunosuppression and catabolism in subjects who have developed
39
40 CCI, consistent with the PICS pathophysiologic phenotype.
41
42
43
44
45
46
47
48

49 **Ethics and dissemination**

50
51 This study has been registered at Clinicaltrials.gov. The University of Florida IRB
52
53 approved this study. All investigators will complete annual training modules regarding the
54
55 ethical conduct of research and Health Insurance Portability and Accountability Act (HIPAA)
56
57
58
59
60

1
2
3 compliance, per IRB requirements. All investigators also complete National Institutes of Health
4
5 conflict of interest disclosure training. Results will be presented at national and international
6
7 conferences and reported in peer-reviewed journals. Dissemination of preliminary results is
8
9 forthcoming.
10
11

12 13 14 15 16 17 **Summary**

18
19
20 Better strategies are needed to improve care for millions of critically ill patients with
21
22 sepsis and septic shock. While in-hospital mortality has decreased, a new phenotype of CCI
23
24 driven by PICS physiology has emerged, and appears to be associated with a substantial burden
25
26 of morbidity and late mortality. Therefore, further investigation is needed to elucidate
27
28 pathophysiology and identify therapeutic approaches for CCI and PICS. Through prospective
29
30 multidisciplinary investigation augmented by automated sepsis surveillance, clinical decision
31
32 support with a computerized sepsis protocol, advanced data management strategies, and robust
33
34 long-term follow-up, the SCIRC seeks to develop novel management strategies and targeted
35
36 therapies for critically ill septic patients.
37
38
39
40
41
42
43

44 **Author contributions**

45
46
47 TO, BAB, AB, MSS, SDA, CL, AMM, PAE, LLM, FAM and SCB contributed to study
48
49 design. TJL, JCM, and TO contributed to manuscript composition. LLM, FAM, and SCB
50
51 provided critical revisions.
52
53
54
55
56
57
58
59
60

References

1. Yeh RW, Sidney S, Chandra M, et al. Population trends in the incidence and outcomes of acute myocardial infarction. *N Engl J Med* 2010;362(23):2155-65.
2. Torio CM, Andrews RM. National Inpatient Hospital Costs: The Most Expensive Conditions by Payer, 2011: Statistical Brief #160. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville (MD), 2006.
3. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. *Crit Care Med* 2001;29(7):1303-10.
4. Kaukonen KM, Bailey M, Pilcher D, et al. Systemic inflammatory response syndrome criteria in defining severe sepsis. *N Engl J Med* 2015;372(17):1629-38.
5. Gentile LF, Cuenca AG, Efron PA, et al. Persistent inflammation and immunosuppression: a common syndrome and new horizon for surgical intensive care. *J Trauma Acute Care Surg* 2012;72(6):1491-501.
6. Rosenthal MD, Moore FA. Persistent inflammatory, immunosuppressed, catabolic syndrome (PICS): A new phenotype of multiple organ failure. *J Adv Nutr Hum Metab* 2015;1(1).
7. Croft CA, Moore FA, Efron PA, et al. Computer versus paper system for recognition and management of sepsis in surgical intensive care. *J Trauma Acute Care Surg* 2014;76(2):311-7; discussion 18-9.
8. McKinley BA, Moore LJ, Sucher JF, et al. Computer protocol facilitates evidence-based care of sepsis in the surgical intensive care unit. *J Trauma* 2011;70(5):1153-66; discussion 66-7.

- 1
2
3
4 9. Gardner-Thorpe J, Love N, Wrightson J, et al. The value of Modified Early Warning Score
5
6 (MEWS) in surgical in-patients: a prospective observational study. *Ann R Coll Surg Engl*
7
8 2006;88(6):571-5.
9
- 10
11 10. Muckart DJ, Bhagwanjee S. American College of Chest Physicians/Society of Critical Care
12
13 Medicine Consensus Conference definitions of the systemic inflammatory response
14
15 syndrome and allied disorders in relation to critically injured patients. *Crit Care Med*
16
17 1997;25(11):1789-95.
18
- 19
20 11. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International
21
22 Sepsis Definitions Conference. *Crit Care Med* 2003;31(4):1250-6.
23
- 24
25 12. Davies MG, Hagen PO. Systemic inflammatory response syndrome. *Br J Surg*
26
27 1997;84(7):920-35.
28
- 29
30 13. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international
31
32 guidelines for management of severe sepsis and septic shock: 2012. *Crit Care Med*
33
34 2013;41(2):580-637.
35
- 36
37 14. Nathens AB, Johnson JL, Minei JP, et al. Inflammation and the Host Response to Injury, a
38
39 large-scale collaborative project: Patient-Oriented Research Core--standard operating
40
41 procedures for clinical care. I. Guidelines for mechanical ventilation of the trauma
42
43 patient. *J Trauma* 2005;59(3):764-9.
44
- 45
46 15. Minei JP, Nathens AB, West M, et al. Inflammation and the Host Response to Injury, a
47
48 Large-Scale Collaborative Project: patient-oriented research core--standard operating
49
50 procedures for clinical care. II. Guidelines for prevention, diagnosis and treatment of
51
52 ventilator-associated pneumonia (VAP) in the trauma patient. *J Trauma* 2006;60(5):1106-
53
54 13; discussion 13.
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
16. Moore FA, McKinley BA, Moore EE, et al. Inflammation and the Host Response to Injury, a large-scale collaborative project: patient-oriented research core--standard operating procedures for clinical care. III. Guidelines for shock resuscitation. *J Trauma* 2006;61(1):82-9.
17. West MA, Shapiro MB, Nathens AB, et al. Inflammation and the host response to injury, a large-scale collaborative project: Patient-oriented research core-standard operating procedures for clinical care. IV. Guidelines for transfusion in the trauma patient. *J Trauma* 2006;61(2):436-9.
18. Shapiro MB, West MA, Nathens AB, et al. V. Guidelines for sedation and analgesia during mechanical ventilation general overview. *J Trauma* 2007;63(4):945-50.
19. Harbrecht BG, Minei JP, Shapiro MB, et al. Inflammation and the host response to injury, a large-scale collaborative project: patient-oriented research core-standard operating procedures for clinical care: VI. Blood glucose control in the critically ill trauma patient. *J Trauma* 2007;63(3):703-8.
20. West MA, Moore EE, Shapiro MB, et al. Inflammation and the host response to injury, a large-scale collaborative project: patient-oriented research core--standard operating procedures for clinical care VII--Guidelines for antibiotic administration in severely injured patients. *J Trauma* 2008;65(6):1511-9.
21. O'Keefe GE, Shelton M, Cuschieri J, et al. Inflammation and the host response to injury, a large-scale collaborative project: patient-oriented research core--standard operating procedures for clinical care VIII--Nutritional support of the trauma patient. *J Trauma* 2008;65(6):1520-8.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
22. Evans HL, Cuschieri J, Moore EE, et al. Inflammation and the host response to injury, a Large-Scale Collaborative Project: patient-oriented research core standard operating procedures for clinical care IX. Definitions for complications of clinical care of critically injured patients. *J Trauma* 2009;67(2):384-8.
 23. Silver GM, Klein MB, Herndon DN, et al. Standard operating procedures for the clinical management of patients enrolled in a prospective study of Inflammation and the Host Response to Thermal Injury. *J Burn Care Res* 2007;28(2):222-30.
 24. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA* 2016;315(8):801-10.
 25. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform* 2009;42(2):377-81.
 26. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *PLoS Med* 2007;4(10):e296.
 27. Jones AE, Trzeciak S, Kline JA. The Sequential Organ Failure Assessment score for predicting outcome in patients with severe sepsis and evidence of hypoperfusion at the time of emergency department presentation. *Crit Care Med* 2009;37(5):1649-54.
 28. Knaus WA, Draper EA, Wagner DP, et al. APACHE II: a severity of disease classification system. *Crit Care Med* 1985;13(10):818-29.
 29. Hays RD, Sherbourne CD, Mazel RM. The RAND 36-Item Health Survey 1.0. *Health Econ* 1993;2(3):217-27.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
30. Kaiser MJ, Bauer JM, Ramsch C, et al. Validation of the Mini Nutritional Assessment short-form (MNA-SF): a practical tool for identification of nutritional status. *J Nutr Health Aging* 2009;13(9):782-8.
31. EuroQol G. EuroQol--a new facility for the measurement of health-related quality of life. *Health Policy* 1990;16(3):199-208.
32. Rasmusson DX, Bylsma FW, Brandt J. Stability of performance on the Hopkins Verbal Learning Test. *Arch Clin Neuropsychol* 1995;10(1):21-6.
33. Lezak MD. *Neuropsychological assessment*. 3rd ed. New York: Oxford University Press, 1995.
34. McDowell I, Kristjansson B, Hill GB, et al. Community screening for dementia: the Mini Mental State Exam (MMSE) and Modified Mini-Mental State Exam (3MS) compared. *J Clin Epidemiol* 1997;50(4):377-83.
35. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am J Clin Oncol* 1982;5(6):649-55.
36. Guralnik JM, Simonsick EM, Ferrucci L, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. *J Gerontol* 1994;49(2):M85-94.
37. Mitsiopoulos N, Baumgartner RN, Heymsfield SB, et al. Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. *J Appl Physiol* (1985) 1998;85(1):115-22.
38. Mourtzakis M, Prado CM, Lieffers JR, et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. *J Appl Physiol Nutr Metab* 2008;33(5):997-1006.

- 1
2
3 39. Mira JC, Gentile LF, Mathias BJ, et al. Sepsis Pathophysiology, Chronic Critical Illness, and
4
5 Persistent Inflammation-Immunosuppression and Catabolism Syndrome. Crit Care Med
6
7
8 2016.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1: The modified early warning signs (MEWS) – sepsis recognition score (SRS) grading scale, adapted from Croft et al.⁷ was used as a screening tool to identify patients who may be developing sepsis. The provider is notified if the patient has a total score ≥ 6 , 3 points in any single category, worsening mental status, or an increase in fraction of inspired oxygen (FiO₂).

Points	3	2	1	0	1	2	3
Temp	< 32	< 35	< 36	36.0-38.4	38.5-38.9	39.0-40.9	≥ 41
HR	< 40	40-44	45-50	51-100	101-110	111-129	≥ 129
RR	≤ 7	8	9	10-14	15-20	21-29	≥ 30
SBP	≤ 70	71-80	81-100	101-160	161-180	181-199	≥ 200
Mental status ^a	unresponsive	responds to noxious stimuli	responds to voice or tap	alert, cooperative	mildly agitated, confused	very agitated, requires restraints	extremely agitated, danger to self or others
WBC	< 1.0 ^b	1.0-2.9 ^b	-	3.0-14.9	15.0-19.9	20.0-39.9	≥ 40

Temp: temperature (°C), HR: heart rate, RR: respiratory rate, SBP: systolic blood pressure (mmHg), WBC: white blood cell count ($\times 10^9/L$). ^aDo not score if the patient is receiving a sedating medication or has a general medical condition affecting mental status (e.g. traumatic brain injury, stroke). ^bDo not score if the patient is receiving oncolytic therapy.

Figure legend

Figure 1: The persistent inflammation, immunosuppression, and catabolism syndrome (PICS), adapted from Rosenthal et al.⁶ and Mira et al.³⁹ MOF: multiple organ failure, SIRS: systemic inflammatory response syndrome, CARS: compensatory anti-inflammatory response syndrome, LTAC: long-term acute care facility.




Figure 1: The persistent inflammation, immunosuppression, and catabolism syndrome (PICS), adapted from Rosenthal et al.⁶ and Mira et al.³⁹ MOF: multiple organ failure, SIRS: systemic inflammatory response syndrome, CARS: compensatory anti-inflammatory response syndrome, LTAC: long-term acute care facility.

182x125mm (120 x 120 DPI)

BMJ Open

Sepsis and Critical Illness Research Center Investigators: protocols and standard operating procedures for a prospective cohort study of sepsis in critically ill surgical patients



Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-015136.R1
Article Type:	Protocol
Date Submitted by the Author:	12-May-2017
Complete List of Authors:	Loftus, Tyler; Department of Surgery Mira, Juan; Department of Surgery Ozrazgat-Baslanti, Tezcan; Department of Anesthesiology Ghita, Gabriella; University of Florida, Department of Biostatistics Wang , Zhongkai; University of Florida, Department of Biostatistics Stortz, Julie; Department of Surgery Brumback, Babette ; Department of Biostatistics Bihorac, Azra; Department of Anesthesiology Segal, Mark; Department of Medicine Anton, Stephen; Institute on Aging Leeuwenburgh, Christiaan; Institute on Aging Mohr, Alicia; Department of Surgery Efron, Philip; Department of Surgery Moldawer, Lyle; Department of Surgery Moore, Frederick; Department of Surgery Brakenridge, Scott; University of Florida, General Surgery
Primary Subject Heading:	Intensive care
Secondary Subject Heading:	Epidemiology, Evidence based practice, Health informatics, Research methods, Surgery
Keywords:	Immunology < BASIC SCIENCES, Health informatics < BIOTECHNOLOGY & BIOINFORMATICS, Adult intensive & critical care < INTENSIVE & CRITICAL CARE, Adult surgery < SURGERY, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, CLINICAL PHYSIOLOGY

SCHOLARONE™
Manuscripts

Sepsis and Critical Illness Research Center Investigators: protocols and standard operating procedures for a prospective cohort study of sepsis in critically ill surgical patients

Short title: SCIRC standard operating procedures

Tyler J. Loftus, MD^{a,b} (Tyler.Loftus@surgery.ufl.edu)

Juan C. Mira, MD^{a,b} (Juan.Mira@surgery.ufl.edu)

Tezcan Ozrazgat-Baslanti, PhD^{a,c} (Tezcan.OzrazgatBaslanti@medicine.ufl.edu)

Gabriella L. Ghita, MPH^d (glghita0429@ufl.edu)

Zhongkai Wang MS^d (zkwang@ufl.edu)

Julie A. Stortz, MD^{a,b} (Julie.Stortz@surgery.ufl.edu)

Babette A. Brumback, PhD^{a,d} (brumback@PHHP.ufl.edu)

Azra Bihorac, MD^{a,c} (abihorac@anest.ufl.edu)

Mark S. Segal, MD, PhD^{a,c} (Mark.Segal@medicine.ufl.edu)

Stephen D. Anton, PhD^{a,f} (santon@ufl.edu)

Christiaan Leeuwenburgh, PhD^{a,f} (cleeuwen@ufl.edu)

Alicia M. Mohr, MD^{a,b} (Alicia.Mohr@surgery.ufl.edu)

Philip A. Efron MD^{a,b} (Philip.Efron@surgery.ufl.edu)

Lyle L. Moldawer, PhD^{a,b} (Lyle.Moldawer@surgery.ufl.edu)

Frederick A. Moore MD^{a,b} (Frederick.Moore@surgery.ufl.edu)

Scott C. Brakenridge, MD, MSCS^{a,b} (Scott.Brakenridge@surgery.ufl.edu)

^aUniversity of Florida Health, Department of Surgery and Sepsis and Critical Illness Research Center in Gainesville, Florida

^bUniversity of Florida Health, Department of Surgery

^cUniversity of Florida Health, Department of Anesthesiology

^dUniversity of Florida Health, Department of Biostatistics

^eUniversity of Florida Health, Department of Medicine

^fUniversity of Florida Health, Institute on Aging

Please address correspondence to:

Scott C. Brakenridge MD, MSCS

University of Florida Health, Gainesville, FL

1600 SW Archer Road Room M-602

Gainesville, FL, 32610-3003

972-415-2447

Scott.Brakenridge@surgery.ufl.edu

This work was supported by P50 GM111152–01 awarded by the National Institute of General Medical Sciences (NIGMS). TJL, JCM, and JAS were supported by a post-graduate training grant (T32 GM-08721) in burns, trauma, and perioperative injury from the NIGMS. The authors have read and understood BMJ policy on declaration of interests and declare that we have no competing interests.

Abstract

Introduction: Sepsis is a common, costly, and morbid cause of critical illness in trauma and surgical patients. Ongoing advances in sepsis resuscitation and critical care support strategies have led to improved in-hospital mortality. However, these patients now survive to enter state of chronic critical illness (CCI), persistent low-grade organ dysfunction, and poor long-term outcomes driven by the persistent inflammation, immunosuppression, and catabolism syndrome (PICS). The Sepsis and Critical Illness Research Center (SCIRC) was created to provide a platform by which the prevalence and pathogenesis of CCI and PICS may be understood at a mechanistic level across multiple medical disciplines, leading to the development of novel management strategies and targeted therapies.

Methods: Here we describe the design, study cohort, and standard operating procedures used in the prospective study of human sepsis at a level 1 trauma center and tertiary care hospital providing care for over 2,600 critically ill patients annually. These procedures include implementation of an automated sepsis surveillance initiative, augmentation of clinical decisions with a computerized sepsis protocol, strategies for direct exportation of quality-filtered data from the electronic medical record to a research database, and robust long-term follow-up.

Ethics and dissemination: This study has been registered at Clinicaltrials.gov, approved by the University of Florida Institutional Review Board, and is actively enrolling subjects.

Dissemination of results is forthcoming.

Strengths and limitations of this study

- Computerized decision support will minimize the influence of variability in management practices
- Robust long-term follow-up will allow for deeper understanding of functional recovery following sepsis
- Investigation of targeted therapies is currently limited by deficiencies in our understanding of sepsis pathophysiology

Introduction

Sepsis as both a cause and complication of surgical intensive care unit admission is common, costly, and morbid. Hospitalization with sepsis has become more common than hospitalization with myocardial infarction, with annual costs over \$20 billion in the United States^{1 2}. Mortality rates for sepsis range from 18-28%, and remain unacceptably high despite more than 30 years of intensive research^{3 4}. Recent advances in resuscitation strategies have improved in-hospital mortality, but sepsis survivors often enter a state of chronic critical illness (CCI) driven by the persistent inflammation, immunosuppression, and catabolism syndrome (PICS)^{5 6} (Figure 1). However, the pathophysiology of these conditions remains incompletely understood. The Sepsis and Critical Illness Research Center (SCIRC) was created to provide a platform to better understand the pathophysiology of PICS. The objective of this prospective cohort study of sepsis in critically ill surgical patients is to understand the prevalence and pathogenesis of PICS at a mechanistic level across multiple medical disciplines, leading to the development of novel management strategies and targeted therapies.

Methods and analysis

Setting

The University of Florida Health Shands Hospital (Gainesville, Florida; U.S.A.) is a Level 1 Trauma and tertiary care center with two trauma/surgical intensive care units (ICU) totaling 48 beds, which serve as the recruitment base for this cohort study. UF Health is the sole

1
2
3 tertiary care center for a greater than 90-mile radius catchment area, including over 1.5 million
4
5 people. Together, the trauma and surgical ICU teams manage over 2,600 critically ill patients
6
7 annually. Each ICU has a dedicated surgical critical care team including a board certified
8
9 attending intensivist, critical care fellows, surgical and anesthesia residents, and advanced
10
11 practice providers (physician assistants and nurse practitioners). These teams collaborate with
12
13 unit-dedicated pharmacists, respiratory therapists, physical therapists, occupational therapists,
14
15 nutritionists, and social workers. Board certified attending acute care surgeons and critical care
16
17 fellows provide in-hospital coverage 24 hours per day, 7 days per week.
18
19
20
21
22
23
24
25

26 Study design and population

27

28
29 This is a prospective, longitudinal cohort study of surgical intensive care unit (ICU)
30
31 patients that develop sepsis. Based on preliminary data and *a priori* power analyses, 400 patients
32
33 will be enrolled over a period of 4 years, with subsequent 12-month individual follow-up.
34
35 Enrollment began in January 2015 and will continue through January 2019, and beyond if
36
37 funding permits. Inclusion criteria are presence in the trauma/surgical intensive care unit, age \geq
38
39 18 years, and diagnosis with sepsis, severe sepsis, or septic shock with subsequent initiation of
40
41 the computerized clinical decision support (CCDS) directed sepsis protocol⁷⁻⁹. Septic patients
42
43 are initially identified by a modified version of the Modified Early Warning Score (MEWS-SRS)
44
45¹⁰, which screens for sepsis based on temperature, heart rate, respiratory rate, blood pressure, and
46
47 level of consciousness (Table 1). In the emergency department and on surgical wards, this score
48
49 is calculated for each patient on arrival, every time vital signs are recorded, and any time a
50
51 patient has an acute change from their baseline physiologic status, prompting further
52
53
54
55
56
57
58
59
60

1
2
3 investigation. Patients identified by the MEWS screening protocol are then directly assessed by
4
5 a physician or advance practice provider for bedside clinical adjudication of the presence of
6
7 sepsis (a systemic inflammatory response with a source of infection), severe sepsis (sepsis-
8
9 induced tissue hypoperfusion or organ dysfunction), or septic shock (severe sepsis with
10
11 persistent arterial hypotension despite volume resuscitation) based on consensus definitions¹¹⁻¹⁴.
12
13 This screening and diagnostic process has been automated and embedded within the UF Health
14
15 electronic medical record (Epic Systems, Verona, WI). All cases that are deemed to have sepsis,
16
17 severe sepsis, or septic shock by the physician or advanced practice provider at the bedside are
18
19 then reviewed in detail by a faculty member of the SCIRC to ensure that the diagnosis was
20
21 appropriate, and are reviewed again at weekly SCIRC sepsis adjudication meetings for the same
22
23 purpose.
24
25
26
27
28
29

30 Exclusion criteria are age <18 years, severe traumatic brain injury (i.e. CT evidence of
31
32 neurologic injury and Glasgow Coma Scale score <8), spinal cord injury resulting in permanent
33
34 sensory and/or motor deficits, sepsis with an uncontrollable source (e.g. unresectable bowel
35
36 ischemia), NY Heart Association class IV heart failure, Child-Pugh Class B or C liver disease,
37
38 known HIV infection with CD4 count <200 cells/mm³, organ transplant recipient on an
39
40 immunosuppressant agent, chemotherapy or radiotherapy within 30 days prior to onset of sepsis,
41
42 expected lifespan <3 months due to severe pre-existing comorbidities, active Do Not Resuscitate
43
44 or Do Not Intubate order, pregnancy, incarceration, or institutionalization. Demographics,
45
46 comorbidities, illness severity, length of stay, and discharge disposition for patients who have
47
48 been enrolled in the study are listed in Table 2.
49
50
51
52
53
54

55 Within the study population, cohort analyses will include comparisons between patients
56
57 who develop CCI versus patients who experience early recovery from sepsis. Among CCI
58
59
60

1
2
3 patients, patients who develop PICS will be compared to patients who do not. In addition,
4
5 inflammatory, immunosuppression, and catabolism biomarkers will be measured in age-matched
6
7 healthy control for comparison to CCI, non-CCI, and PICS patients.
8
9

10 11 12 13 14 Computerized clinical decision support (CCDS) sepsis protocol 15

16
17
18 Patients who are diagnosed with sepsis, severe sepsis, or septic shock are started on a
19
20 computerized clinical decision support protocol, as previously described ⁷. This system was
21
22 modified from a sepsis management protocol originally implemented at the Methodist Hospital
23
24 in Houston, Texas ⁸. In brief, mobile bedside computer workstations were programed with
25
26 sepsis protocol algorithm logic that interacts with the patient and clinician by mapping clinical
27
28 workflow and recommendations to patient physiology and clinical interventions. The sepsis
29
30 protocol algorithm logic was developed by a multidisciplinary team of surgeons, intensivists,
31
32 advanced practitioners, nurses, respiratory therapists, pharmacists, pathologists, and computer
33
34 engineers, based on Surviving Sepsis Campaign guidelines ¹⁴. The algorithm produces a
35
36 recommendation; the clinician may accept or modify the recommendation, tailoring care to
37
38 individual patient-specific factors. The selected intervention is then imputed, and the
39
40 computerized clinical workflow and recommendations continue to evolve.
41
42
43
44
45

46
47 The computerized sepsis protocol is the platform for clinical decisions regarding initial
48
49 volume resuscitation and antibiotic therapy initiation. For all other clinical decisions, the SCIRC
50
51 developed protocols based on standard operating procedures from the Inflammation and the Host
52
53 Response to Injury Collaborative Research Program ¹⁵⁻²⁴. SCIRC protocols include a daily
54
55 spontaneous breathing trial protocol (Supplementary figure 1), delirium protocol (Supplementary
56
57
58
59
60

1
2
3 table 1)^{25 26}, product transfusion protocol (Table 3), and a nutritional support protocol
4
5 (Supplementary table 2)²⁷.
6
7
8
9

10 Subject recruitment

11
12
13 When a patient is diagnosed with sepsis, a page notification is sent to a team of research
14 nurses who respond to evaluate for study enrollment 24 hours per day, 7 days per week. The
15 research nurse on-call evaluates inclusion and exclusion criteria. If the patient qualifies, the
16 research nurse seeks to obtain informed consent from the patient (if able) or legally authorized
17 representative. Similar to the Inflammation and Host Response to Injury program, a 96-hour
18 deferral of informed consent exists for initial sample and data collection based upon previous
19 precedent at this institution, and approved by the institutional review board (IRB)¹⁵⁻¹⁷. If
20 consent is not obtained within 96 hours, all initial blood samples and patient data are destroyed.
21 If consent is initially obtained from the legally authorized representative and the patient regains
22 decision-making capacity, the patient has the opportunity to withdraw from the study at that
23 time. Study subjects may choose to participate during hospital admission with or without long-
24 term follow-up, though long-term follow-up is encouraged, per study objectives.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

42 Within the first seven days, all study subjects undergo prospective clinical adjudication to
43 confirm proper diagnosis, source identification, and severity classification of sepsis during
44 weekly SCIRC adjudication and retention committee meetings. As this study was designed and
45 initiated prior to the Sepsis-3 consensus statement, sepsis severity is classified by previously
46 established consensus definitions¹¹⁻¹⁴. However, data collected during the course of the study
47 will allow for subsequent classification and comparison to the subsequently released Sepsis-3
48 consensus statement, including assessment of qSOFA scores^{28 29}.
49
50
51
52
53
54
55
56
57
58
59
60

Data procurement and management

Data describing baseline characteristics, management, and outcomes for each study subject are prospectively collected, recorded, and managed using the REDCapTM (REDCap consortium; www.projectredcap.org) research electronic case report form platform³⁰. In collaboration with the University of Florida Clinical and Translational Science Institute (CTSI), our center developed an automated data collection and integration system that extracts clinical data from the electronic medical record and uploads the data to REDCap over a secure server on a daily basis. Raw data from the electronic medical record (EMR), including information on patient laboratory results, vital signs, medications, and information related to hospital and ICU admission and discharge are directly uploaded to the SCIRC database by the University of Florida Health Integrated Data Repository (IDR). The SCIRC database includes over 800 data fields describing the vital signs, clinical signs and symptoms of sepsis, medical history, laboratory values, microbiologic analyses, cardiopulmonary resuscitation parameters, procedural interventions, medications, infusions, and outcomes for each patient. Parameters available in the EMR are transferred to the SCIRC database after compilation and quality filtering via the IDR system. Data from biologic sampling analyses performed by the Bioanalytical Core (e.g. flow cytometry, ELISA, multiplex, and gene analyses) are also transferred to the SCIRC drive as they are completed. The SCIRC database gives each project access to its own protected folder and to a bridge folder in which data can be placed for transfer to the Database Management and Biostatistics Core personnel for quality control and statistical analyses. The quality and accuracy of the transferred data is validated at regular intervals by the Database Management and Biostatistics Core by identifying potential outlier values and reviewing the source data with

1
2
3 SCIRC faculty. Parameters that are not available in the electronic medical record are manually
4 extracted and entered into the REDCap case report form platform. Data regarding the inpatient
5 hospital course prior to protocol initiation are also collected. For patients transferred from
6 another facility, this includes records from the outside facility regarding the initial signs and
7 symptoms of sepsis, microbiologic findings, antibiotic administration parameters, and source
8 control procedures.
9
10
11
12
13
14
15
16
17
18
19
20
21

22 Biomarker sampling, processing, and analysis

23
24
25 Tissue samples are collected at scheduled intervals for biomarkers analyses of
26 inflammation (e.g. plasma tumor necrosis factor-alpha, interleukin (IL)-1, IL-2, IL-3, IL-5, IL-6,
27 IL-10, IL-12, interferon-gamma, macrophage inflammatory protein 1-alpha),
28 immunosuppression (e.g. granulocytic and monocytic myeloid-derived suppressor cells in whole
29 blood, expression of PD-1³¹ and PDL-1 on blood monocytes and CD66b⁺ neutrophils) and
30 catabolism (e.g. serum prealbumin, urine 3-methylhistidine, skeletal muscle high-resolution
31 respirometry *in situ*, assessment of muscle morphology and myosin/actin ratio by histochemistry,
32 and measurement of FoxO3A, MuRF1, MAFBx, BNIP, calpains, and 20S proteasome activity)
33 from 12 hours out to 42 days or inpatient discharge for non- muscle samples. Muscle samples
34 are obtained 28 days after sepsis protocol initiation. Skeletal muscle samples weighing 150-250
35 mg are obtained from the vastus lateralis at the midpoint between the patella and the greater
36 trochanter of the femur by trained practitioners using sterile technique under local anesthesia, as
37 previously described³². A portion is immediately permeabilized for high resolution respiration
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 measurements, a portion is mounted in embedding medium and frozen in isopentane for
4
5 histochemical analysis, and the remaining tissue is frozen in liquid nitrogen and stored at -80°C.
6
7

8
9 For purposes of sample collection, time zero coincides with initiation of the sepsis
10 protocol. Blood samples and laboratory measurements are obtained at the following time points,
11 relative to sepsis protocol and study initiation: 12 hours, 1 day, 4 days, 7 days, 14 days, 21 days,
12 28 days, 35 days, and 42 days. Initial sample processing, including centrifugation, labeling, and
13 freezing of patient samples, is performed 24 hours per day, 7 days per week at an on-site sample
14 processing laboratory located within the trauma ICU. This laboratory contains a -80° freezer, a
15 microfuge, a refrigerated centrifuge, and an environmental hood. Flow cytometry is performed
16 on fresh samples, and all other samples are stored in the -80° freezer, and subsequently
17 transported to the Bioanalytics core or individual project laboratories as appropriate. Collected
18 specimens are annotated, labeled, and stored according to best practice guidelines³³. Stored
19 samples are maintained in a biobank that will remain available for future testing. Standard
20 training is provided to all laboratory staff regarding machine calibration, sample processing,
21 operator safety, and quality control. Serum and plasma samples are collected in a fully filled
22 collection tube, inverted 5-10 times, and then maintained in a closed tube in vertical position
23 until centrifugation. Samples are analyzed in parallel with reagents from the same batch by the
24 same technician. Analytic methods include flow cytometry, enzyme-linked immunosorbent
25 assay, multiplex, and gene expression array (NanoString Technologies, Seattle, WA, and
26 Affymetrix, Cleveland, OH). The analytic plan followed the STROBE recommendations for
27 observational cohort studies³⁴.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

53
54
55
56
57 Subject retention, clinical assessments, and long-term follow-up
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

During the index hospitalization, clinical assessments focus on host factors (e.g. age, gender, comorbidities, hospital course prior to ICU admission), infection characteristics (e.g. presumed type of infection, microbiologic data, antibiotic therapy), sepsis severity (e.g. hemodynamic parameters, vasopressor support, laboratory measures of hypoxemia and tissue ischemia, Sequential Organ Failure Assessment (SOFA) scores³⁵, APACHE II scores³⁶), volume status by protocolized bedside echocardiography, procedural interventions to obtain source control, nutritional parameters (e.g. nutrition provided by gastric, post-pyloric, and parenteral routes, weekly caloric and protein goals versus actual calories and protein administered, 24-hour urine collection to assess nitrogen balance, indirect calorimetry, and changes in body mass index and ideal body weight), and short-term outcomes (e.g. infectious complications, non-infectious complications, ICU length of stay, days on mechanical ventilation, change in SOFA score over time, in-hospital mortality, discharge disposition).

32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Bedside echocardiography is performed by the transesophageal approach for intubated patients with an intact esophagus and stomach, no known or suspected gastroesophageal variceal disease, and low risk for pathologically increased intracranial pressures. Echocardiography is performed by the transthoracic approach for all other patients. Assessments include the presence of pericardial fluid, characterization of the right ventricle size as normal, collapsible, or enlarged, characterization of right and left ventricle contractility as normal, poor, or hyperdynamic, description of the superior vena cava collapsibility index as less than or equal to 36%, quantification of fractional area change (the difference in left ventricular area at end-diastole versus end-systole, divided by end-diastolic area), an interpretation of the findings as representing euvoolemia, hypovolemia, or hypervolemia, and a plan to start, discontinue, increase,

1
2
3 or decrease intravenous fluid therapy, vasopressor therapy, and inotrope therapy based on
4
5
6 echocardiography findings.
7

8
9 A retention committee creates an individualized follow-up plan for each study subject
10
11 prior to discharge from the hospital. The retention committee meets twice per week to discuss
12
13 all active study subjects, with special attention to subjects for whom long-term follow-up may be
14
15 jeopardized by geographic and social impediments. Phone contact encounters are scheduled and
16
17 used to predict retention problems. Parking and transportation costs are provided to the study
18
19 subjects to maximize access to the research center. Members of the retention committee are
20
21 trained to recognize and address psychosocial issues and provide emotional support as needed.
22
23 When medical and/or mental health problems necessitating further treatment are identified, the
24
25 retention committee provides referrals to the appropriate specialists, and ensures that care is
26
27 provided in a timely fashion.
28
29
30
31
32

33 Long-term follow-up outpatient clinic visits occur at 3 months, 6 months, and 12 months
34
35 at the facilities of the University of Florida Institute on Aging. Clinical assessments at these time
36
37 points will focus on functional recovery from sepsis by performing a battery of tests including
38
39 the Rand 36 Item SF health Survey³⁷, Mini Nutritional Assessment³⁸, EQ-5D-3L Health
40
41 Questionnaire³⁹, Hopkins Verbal Learning Test⁴⁰, Controlled Oral Word Association test⁴¹,
42
43 Modified Mini-Mental State Exam⁴², ECOG/WHO/Zubrod score⁴³, Short Physical Performance
44
45 Battery⁴⁴, hand grip strength measurement, and body composition measurements with the BIA
46
47 450 bioimpedance analyzer (Biodynamics Corporation, Shoreline, WA). If patients are
48
49 unwilling or unable to return for outpatient clinical follow-up, home-visits are scheduled (up to
50
51 2-hour drive radius), or subjective data is collected via telephone interview.
52
53
54
55
56
57
58
59
60

1
2
3 To identify and evaluate the progression of sarcopenia, we will perform computed
4 tomography (CT) morphometric assessments of psoas and abdominal wall lean muscle mass at
5 baseline, 3 months, and 12 months, using SliceOmatic software (version 5.0 rev 6a; Tomovision,
6 Magog, Quebec, Canada). Standard of care CT scans of the abdomen and pelvis conducted for
7 diagnostic purposes while the patient was hospitalized were used for this analysis. Two of these
8 CT scans were used: the baseline scan was performed within three days of sepsis protocol onset;
9 the second scan was performed within seven to fourteen days of the baseline scan. To calculate
10 the total skeletal muscle cross-sectional area (cm^2), trained investigators identified and quantified
11 all skeletal muscles (psoas, paraspinal, and abdominal wall muscles) at the level of the third
12 lumbar (L3) vertebra where both transverse processes were visualized using established
13 Hounsfield unit (-29 to 150) attenuation thresholds for skeletal muscle tissue⁴⁵. The L3
14 vertebral level was chosen because skeletal muscle visualized at this axial plane has been shown
15 to correlate with whole-body muscle mass⁴⁶. Skeletal muscle index (SMI, cm^2/m^2) was then
16 calculated by normalizing the total skeletal muscle cross-sectional area (cm^2) to patient height
17 squared (m^2). Psoas muscle index (PMI, cm^2/m^2) was also calculated by normalizing only the
18 psoas muscle cross-sectional area (cm^2) to patient height squared (m^2).
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 Outcome definitions and analytic design

46
47
48 The primary outcomes of interest are the development of chronic critical illness (CCI)
49 and 1-year mortality rates after the development of sepsis. CCI is defined as an extended course
50 of critical illness with persistent organ dysfunction requiring intensive care resources. Extended
51 course of illness requiring intensive care resources is defined as total ICU days >14 days or being
52
53
54
55
56
57
58
59
60

1
2
3 discharged to another hospital, long term acute care hospital, or hospice. Persistent organ
4
5 dysfunction is defined as having a SOFA score of at least 2 in any organ system with the
6
7 exception of at least 1 for cardiovascular system on day 14 in ICU after protocol onset or last
8
9 SOFA score available, whichever comes first. Subjects are deemed to have developed CCI if
10
11 they are discharged to dispositions associated with poor outcomes (e.g. long term acute care
12
13 facility, skilled nursing facility) prior to ICU day 14 with ongoing evidence of organ dysfunction,
14
15 as described above. Mortality at 1-year will be determined by prospective follow-up, or from the
16
17 United States Social Security Death Index for those lost to follow-up.
18
19
20
21
22

23 Secondary outcomes of interest include changes in health, function and quality of life
24
25 assessments at 1-year after sepsis onset. Analyses will include the development of biomarker
26
27 and clinical prediction models for the development of CCI, as well as prediction models and the
28
29 development of a “CCI score” at ICU day 14 to predict 1-year mortality and poor functional
30
31 outcomes. Additionally, biomarker analyses at day 14 will seek to characterize the presence of
32
33 persistent inflammation, immunosuppression and catabolism in subjects who have developed
34
35 CCI, consistent with the PICS pathophysiologic phenotype.
36
37
38
39
40
41
42
43

44 **Ethics and dissemination**

45
46
47 This study has been registered at Clinicaltrials.gov (NCT02276417). The University of
48
49 Florida IRB approved this study. This work was supported by P50 GM111152–01 awarded by
50
51 the National Institute of General Medical Sciences (NIGMS). TJL, JCM, and JAS were
52
53 supported by a post-graduate training grant (T32 GM-08721) in burns, trauma, and perioperative
54
55 injury from the NIGMS. The authors have read and understood BMJ policy on declaration of
56
57
58
59
60

1
2
3 interests and declare that the authors have no competing interests. All investigators will complete
4 annual training modules regarding the ethical conduct of research and Health Insurance
5 Portability and Accountability Act (HIPAA) compliance, per IRB requirements. All
6
7
8 investigators also complete National Institutes of Health conflict of interest disclosure training.
9
10
11 Results will be presented at national and international conferences and reported in peer-reviewed
12
13
14 journals. Dissemination of preliminary results is forthcoming.
15
16
17
18
19
20

21 **Summary**

22
23
24
25 Better strategies are needed to improve care for millions of critically ill patients with
26
27 sepsis and septic shock. While in-hospital mortality has decreased, a new phenotype of CCI
28
29 driven by PICS physiology has emerged, and appears to be associated with a substantial burden
30
31 of morbidity and late mortality. Therefore, further investigation is needed to elucidate
32
33 pathophysiology and identify therapeutic approaches for CCI and PICS. Through prospective
34
35 multidisciplinary investigation augmented by automated sepsis surveillance, clinical decision
36
37 support with a computerized sepsis protocol, advanced data management strategies, and robust
38
39 long-term follow-up, the SCIRC seeks to develop novel management strategies and targeted
40
41
42 therapies for critically ill septic patients.
43
44
45
46
47
48

49 **Author contributions**

50
51
52 TO, GG, ZW, BAB, AB, MSS, SDA, CL, AMM, PAE, LLM, FAM and SCB contributed
53
54 to study design. TJL, JCM, and TO contributed to manuscript composition. LLM, FAM, and
55
56
57 SCB provided critical revisions.
58
59
60

References

1. Yeh RW, Sidney S, Chandra M, et al. Population trends in the incidence and outcomes of acute myocardial infarction. *N Engl J Med* 2010;362(23):2155-65.
2. Torio CM, Andrews RM. National Inpatient Hospital Costs: The Most Expensive Conditions by Payer, 2011: Statistical Brief #160. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville (MD), 2006.
3. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. *Crit Care Med* 2001;29(7):1303-10.
4. Kaukonen KM, Bailey M, Pilcher D, et al. Systemic inflammatory response syndrome criteria in defining severe sepsis. *N Engl J Med* 2015;372(17):1629-38.
5. Gentile LF, Cuenca AG, Efron PA, et al. Persistent inflammation and immunosuppression: a common syndrome and new horizon for surgical intensive care. *J Trauma Acute Care Surg* 2012;72(6):1491-501.
6. Rosenthal MD, Moore FA. Persistent inflammatory, immunosuppressed, catabolic syndrome (PICS): A new phenotype of multiple organ failure. *J Adv Nutr Hum Metab* 2015;1(1).
7. Croft CA, Moore FA, Efron PA, et al. Computer versus paper system for recognition and management of sepsis in surgical intensive care. *J Trauma Acute Care Surg* 2014;76(2):311-7; discussion 18-9.
8. McKinley BA, Moore LJ, Sucher JF, et al. Computer protocol facilitates evidence-based care of sepsis in the surgical intensive care unit. *J Trauma* 2011;70(5):1153-66; discussion 66-7.
9. Sucher JF, Moore FA, Todd SR, et al. Computerized clinical decision support: a technology to implement and validate evidence based guidelines. *J Trauma* 2008;64(2):520-37.
10. Gardner-Thorpe J, Love N, Wrightson J, et al. The value of Modified Early Warning Score (MEWS) in surgical in-patients: a prospective observational study. *Ann R Coll Surg Engl* 2006;88(6):571-5.
11. Muckart DJ, Bhagwanjee S. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference definitions of the systemic inflammatory response syndrome and allied disorders in relation to critically injured patients. *Crit Care Med* 1997;25(11):1789-95.
12. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. *Crit Care Med* 2003;31(4):1250-6.
13. Davies MG, Hagen PO. Systemic inflammatory response syndrome. *Br J Surg* 1997;84(7):920-35.
14. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. *Crit Care Med* 2013;41(2):580-637.

15. Nathens AB, Johnson JL, Minei JP, et al. Inflammation and the Host Response to Injury, a large-scale collaborative project: Patient-Oriented Research Core--standard operating procedures for clinical care. I. Guidelines for mechanical ventilation of the trauma patient. *J Trauma* 2005;59(3):764-9.
16. Minei JP, Nathens AB, West M, et al. Inflammation and the Host Response to Injury, a Large-Scale Collaborative Project: patient-oriented research core--standard operating procedures for clinical care. II. Guidelines for prevention, diagnosis and treatment of ventilator-associated pneumonia (VAP) in the trauma patient. *J Trauma* 2006;60(5):1106-13; discussion 13.
17. Moore FA, McKinley BA, Moore EE, et al. Inflammation and the Host Response to Injury, a large-scale collaborative project: patient-oriented research core--standard operating procedures for clinical care. III. Guidelines for shock resuscitation. *J Trauma* 2006;61(1):82-9.
18. West MA, Shapiro MB, Nathens AB, et al. Inflammation and the host response to injury, a large-scale collaborative project: Patient-oriented research core-standard operating procedures for clinical care. IV. Guidelines for transfusion in the trauma patient. *J Trauma* 2006;61(2):436-9.
19. Shapiro MB, West MA, Nathens AB, et al. V. Guidelines for sedation and analgesia during mechanical ventilation general overview. *J Trauma* 2007;63(4):945-50.
20. Harbrecht BG, Minei JP, Shapiro MB, et al. Inflammation and the host response to injury, a large-scale collaborative project: patient-oriented research core-standard operating procedures for clinical care: VI. Blood glucose control in the critically ill trauma patient. *J Trauma* 2007;63(3):703-8.
21. West MA, Moore EE, Shapiro MB, et al. Inflammation and the host response to injury, a large-scale collaborative project: patient-oriented research core--standard operating procedures for clinical care VII--Guidelines for antibiotic administration in severely injured patients. *J Trauma* 2008;65(6):1511-9.
22. O'Keefe GE, Shelton M, Cuschieri J, et al. Inflammation and the host response to injury, a large-scale collaborative project: patient-oriented research core--standard operating procedures for clinical care VIII--Nutritional support of the trauma patient. *J Trauma* 2008;65(6):1520-8.
23. Evans HL, Cuschieri J, Moore EE, et al. Inflammation and the host response to injury, a Large-Scale Collaborative Project: patient-oriented research core standard operating procedures for clinical care IX. Definitions for complications of clinical care of critically injured patients. *J Trauma* 2009;67(2):384-8.
24. Silver GM, Klein MB, Herndon DN, et al. Standard operating procedures for the clinical management of patients enrolled in a prospective study of Inflammation and the Host Response to Thermal Injury. *J Burn Care Res* 2007;28(2):222-30.

- 1
- 2
- 3
- 4 25. Ely EW, Margolin R, Francis J, et al. Evaluation of delirium in critically ill patients:
5 validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU).
6 Crit Care Med 2001;29(7):1370-9.
- 7
- 8 26. Sessler CN, Gosnell MS, Grap MJ, et al. The Richmond Agitation-Sedation Scale: validity
9 and reliability in adult intensive care unit patients. Am J Respir Crit Care Med
10 2002;166(10):1338-44.
- 11
- 12 27. Rahman A, Hasan RM, Agarwala R, et al. Identifying critically-ill patients who will benefit
13 most from nutritional therapy: Further validation of the "modified NUTRIC" nutritional
14 risk assessment tool. Clin Nutr 2016;35(1):158-62.
- 15
- 16 28. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus
17 Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016;315(8):801-10.
- 18
- 19 29. Finkelsztain EJ, Jones DS, Ma KC, et al. Comparison of qSOFA and SIRS for predicting
20 adverse outcomes of patients with suspicion of sepsis outside the intensive care unit. Crit
21 Care 2017;21(1):73.
- 22
- 23 30. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)--a
24 metadata-driven methodology and workflow process for providing translational research
25 informatics support. J Biomed Inform 2009;42(2):377-81.
- 26
- 27 31. Mansur A, Hinz J, Hillebrecht B, et al. Ninety-day survival rate of patients with sepsis relates
28 to programmed cell death 1 genetic polymorphism rs11568821. J Investig Med
29 2014;62(3):638-43.
- 30
- 31 32. Anton SD, Manini TM, Milsom VA, et al. Effects of a weight loss plus exercise program on
32 physical function in overweight, older women: a randomized controlled trial. Clin Interv
33 Aging 2011;6:141-9.
- 34
- 35 33. 2012 best practices for repositories collection, storage, retrieval, and distribution of
36 biological materials for research international society for biological and environmental
37 repositories. Biopreserv Biobank 2012;10(2):79-161.
- 38
- 39 34. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational
40 Studies in Epidemiology (STROBE) statement: guidelines for reporting observational
41 studies. PLoS Med 2007;4(10):e296.
- 42
- 43 35. Jones AE, Trzeciak S, Kline JA. The Sequential Organ Failure Assessment score for
44 predicting outcome in patients with severe sepsis and evidence of hypoperfusion at the
45 time of emergency department presentation. Crit Care Med 2009;37(5):1649-54.
- 46
- 47 36. Knaus WA, Draper EA, Wagner DP, et al. APACHE II: a severity of disease classification
48 system. Crit Care Med 1985;13(10):818-29.
- 49
- 50 37. Hays RD, Sherbourne CD, Mazel RM. The RAND 36-Item Health Survey 1.0. Health Econ
51 1993;2(3):217-27.
- 52
- 53 38. Kaiser MJ, Bauer JM, Ramsch C, et al. Validation of the Mini Nutritional Assessment short-
54 form (MNA-SF): a practical tool for identification of nutritional status. J Nutr Health
55 Aging 2009;13(9):782-8.
- 56
- 57
- 58
- 59
- 60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
39. EuroQol G. EuroQol--a new facility for the measurement of health-related quality of life. *Health Policy* 1990;16(3):199-208.
 40. Rasmusson DX, Bylsma FW, Brandt J. Stability of performance on the Hopkins Verbal Learning Test. *Arch Clin Neuropsychol* 1995;10(1):21-6.
 41. Lezak MD. *Neuropsychological assessment*. 3rd ed. New York: Oxford University Press, 1995.
 42. McDowell I, Kristjansson B, Hill GB, et al. Community screening for dementia: the Mini Mental State Exam (MMSE) and Modified Mini-Mental State Exam (3MS) compared. *J Clin Epidemiol* 1997;50(4):377-83.
 43. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am J Clin Oncol* 1982;5(6):649-55.
 44. Guralnik JM, Simonsick EM, Ferrucci L, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. *J Gerontol* 1994;49(2):M85-94.
 45. Mitsiopoulos N, Baumgartner RN, Heymsfield SB, et al. Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. *J Appl Physiol* (1985) 1998;85(1):115-22.
 46. Mourtzakis M, Prado CM, Lieffers JR, et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. *Appl Physiol Nutr Metab* 2008;33(5):997-1006.
 47. Mira JC, Gentile LF, Mathias BJ, et al. Sepsis Pathophysiology, Chronic Critical Illness, and Persistent Inflammation-Immunosuppression and Catabolism Syndrome. *Crit Care Med* 2016.

Table 1: The modified early warning signs (MEWS) – sepsis recognition score (SRS) grading scale, adapted from Croft et al.⁷ was used as a screening tool to identify patients who may be developing sepsis. The provider is notified if the patient has a total score ≥ 6 , 3 points in any single category, worsening mental status, or an increase in fraction of inspired oxygen (FiO₂).

Points	3	2	1	0	1	2	3
Temp	< 32	< 35	< 36	36.0-38.4	38.5-38.9	39.0-40.9	≥ 41
HR	< 40	40-44	45-50	51-100	101-110	111-129	≥ 129
RR	≤ 7	8	9	10-14	15-20	21-29	≥ 30
SBP	≤ 70	71-80	81-100	101-160	161-180	181-199	≥ 200
Mental status ^a	unresponsive	responds to noxious stimuli	responds to voice or tap	alert, cooperative	mildly agitated, confused	very agitated, requires restraints	extremely agitated, danger to self or others
WBC	< 1.0 ^b	1.0-2.9 ^b	-	3.0-14.9	15.0-19.9	20.0-39.9	≥ 40

Temp: temperature (°C), HR: heart rate, RR: respiratory rate, SBP: systolic blood pressure (mmHg), WBC: white blood cell count ($\times 10^9/L$). ^aDo not score if the patient is receiving a sedating medication or has a general medical condition affecting mental status (e.g. traumatic brain injury, stroke). ^bDo not score if the patient is receiving oncolytic therapy.

Table 2: Characteristics of enrolled patients.

Demographics	All patients n=216
Age in years, mean (SD)	59.3 (15.2)
Male, n (%)	116 (53.7)
Race, n (%)	
Caucasian (White)	191 (88.4)
African American	20 (9.3)
Asian	1 (0.5)
Pacific Islander	0 (0)
Other	3 (1.4)
BMI, median (25 th , 75 th)	29.3 (24.8, 35.8)
Charlson comorbidity index, mean (SD)	4.3 (3.0)
APACHE II score (24 hrs), mean (SD)	18.0 (8.1)
Inter-facility hospital transfer, n (%)	95 (44.0)
Hospital-acquired sepsis*, n (%)	88 (40.7)
ICU LOS, median (25 th , 75 th)	7 (3.5, 18)
Hospital LOS, median (25 th , 75 th)	17 (8, 29)
Discharge disposition, n (%)	
“Good” disposition	117 (54.2)
Home	38 (17.6)
Home healthcare services	69 (31.2)
Rehab	10 (4.6)
“Poor” disposition	99 (45.8)
Long term acute care facility	30 (13.9)
Skilled nursing facility	37 (17.1)
Another Hospital	9 (4.2)
Hospice	7 (3.2)
Death	16 (7.4)

SD: standard deviation, BMI: body mass index, APACHE: Acute Physiology and Chronic Health Evaluation, ICU: intensive care unit, LOS: length of stay. *Sepsis onset ≥ 48 hours after hospital admission.

Table 3: Indications for blood product transfusion.

Blood product	Indications for transfusion
Red blood cells	Hb <7 g/dL or HCT <21% Hb <10 g/dL or HCT <30% and symptomatic cardiovascular disease Acute blood loss >30% of total blood volume
Plasma (minimum dose 10-20 mL/kg)	INR >1.7 and active bleeding or immediately prior to a procedure Thrombotic thrombocytopenic purpura Factor deficiency for which no specific concentrate is available
Cryoprecipitate	Fibrinogen <100 mg/dL Factor XIII deficiency Perioperative management


Hb: hemoglobin, HCT: hematocrit, INR: international normalized ratio.

Figure legends

Figure 1: The persistent inflammation, immunosuppression, and catabolism syndrome (PICS), adapted from Rosenthal et al.⁶ and Mira et al.⁴⁷ MOF: multiple organ failure, SIRS: systemic inflammatory response syndrome, CARS: compensatory anti-inflammatory response syndrome, LTAC: long-term acute care facility.

Supplementary figure 1: Protocol for daily spontaneous breathing trials.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



MOF –multiple organ failure; PICS – persistent inflammation, immune suppression, and catabolism syndrome; LTAC – long term acute care facility

Figure 1: The persistent inflammation, immunosuppression, and catabolism syndrome (PICS), adapted from Rosenthal et al.⁶ and Mira et al.⁴⁴ MOF: multiple organ failure, SIRS: systemic inflammatory response syndrome, CARS: compensatory anti-inflammatory response syndrome, LTAC: long-term acute care facility.

254x338mm (300 x 300 DPI)

Supplementary table 1: Delirium protocol.

Step 1: Non-pharmacological interventions for delirium prevention and treatment

General

- Perform daily sedation holidays, unless contraindicated
- Avoid over-treatment and under-treatment of pain

Orientation

- Encourage communication
- Have familiar objects from the patient's home in the hospital room
- Frequently re-orient the patient to date, time, and caretakers
- Attempt consistency in staff
- Provide visual and auditory aids
- Allow television during the day with daily news or non-verbal music

Environment

- Encourage early mobilization (e.g. ambulation, range of motion exercises, minimize use of immobilizing equipment, ensure timely removal of catheters, order physical therapy and occupational therapy consults)
- Optimize sleep hygiene
 - Minimize noise and interruption
 - Keep lights on and window shades up during the day
 - Keep lights off and window shades closed at night

Clinical parameters

- Maintain euvolemia
- Maintain adequate systolic blood pressure
- Maintain adequate oxygen saturation
- Treat underlying metabolic derangements and infections

Step 2: Patient assessment

Nursing responsibilities

- Assess delirium using Confusion Assessment Method for the Intensive Care Unit (CAM-ICU)⁴⁵ every nursing shift, during sedation holidays if applicable
- Document screening results in the electronic medical record
- Report delirium positive results to the physician or advanced practitioner
- Assess for other causes of neurological status changes (e.g. hypoxia, vasospasm, stroke, seizure, infection, hypoglycemia, myocardial

infarction, pulmonary embolism)

- Assess patient for extra-pyramidal symptoms (e.g. acute dystonia, akathisia, parkinsonism, tardive dyskinesia), drug-induced rigidity, and high fever at least twice daily (every nursing shift) and when there is a change in clinical status

Physician or advanced practitioner responsibilities

- Assess the patient for non-delirium causes of neurological status changes
- Order appropriate delirium intervention(s) if applicable (Step 3)

Step 3: Interventions by CAM-ICU assessment result

Unable to assess delirium (Richmond Agitation Sedation Scale (RASS)⁴⁶ score -4 or -5)

- Lighten sedation, if applicable, to obtain goal level of sedation
- Continue non-pharmacological interventions for delirium prevention
- Continue daily sedation holidays, unless contraindicated

CAM-ICU delirium negative

- If applicable, continue sedation and analgesia protocols for treatment of anxiety and pain
- Continue non-pharmacological interventions for delirium prevention
- Continue twice daily delirium assessments

CAM-ICU delirium positive

All delirium positive patients

- Implement non-pharmacologic interventions for the prevention and treatment of delirium
- Assess patient for non-delirium causes of neurological status changes
- Ensure adequate pain control
- Discontinue or minimize use of potentially deliriogenic drugs
 - Avoid the use of benzodiazepines
 - Consider the use of propofol if sedation is required

-AND-

Tailored delirium treatment based on RASS score

- Delirium positive and RASS +2 to +4 [agitated]

- Assess pain
 - Pain: treat with analgesics and reassess for delirium
 - No pain: consider treatment with an antipsychotic agent (see next section)
- Provide adequate sedation for protection of the patient and staff
- Delirium positive and RASS 0 or +1 [awake and alert]
 - Ensure adequate pain control
 - Consider treatment with an antipsychotic agent (see next section)
- Delirium positive and RASS -1 to -3 [sedated]
 - Reassess sedation goal and consider adjustment of sedation regimen
 - Perform daily sedation holidays

Treatment of delirium with antipsychotic medications

General considerations

- For patients with alcohol withdrawal delirium (delirium tremens) or traumatic brain injury, use protocols specific for those disease processes
- For transplant patients, discuss with the transplant service before ordering medications
- For pregnant patients, carefully assess risks and benefits of medications and discuss with the Obstetrics and Gynecology service prior to ordering medications
- Use lower antipsychotic doses for elderly patients
- Prior to initiation of antipsychotics, obtain baseline QTc and monitor regularly thereafter
 - If QTc >490 mSec on bedside monitor, obtain 12-lead electrocardiogram
 - If QTc >500 mSec on 12-lead electrocardiogram
 - Alert physician or advanced practitioner
 - Hold all non-essential QTc prolonging medications and do not administer atypical antipsychotics
 - Repeat electrocardiogram in 6-12 hours
 - Consider supplemental magnesium administration
- Perform regular assessments for extra-pyramidal symptoms, drug-induced rigidity, and high fever
- Obtain liver function tests at baseline and at regular intervals according to the pharmacologic profile of the medication in use
- Consider consultation with the Psychiatry service if:

- Antipsychotic agents are ineffective
- The patient has a contraindication to antipsychotic use
- The patient has a baseline psychiatric disorder for which the patient is already receiving antipsychotics

Antipsychotic discontinuation

Once delirium has resolved, taper to the minimum effective dose over 3 to 5 days. Therapy should be discontinued approximately two weeks after discharge from the ICU or prior to discharge home to avoid the development of long-term adverse effects, including:

- Sedation/fatigue
- Weight gain
- Glucose intolerance
- Dyslipidemia
- Sudden cardiac death
- Increased mortality among elderly patients with dementia

Supplementary table 2: Nutrition protocol.

Feeding initiation and advancement parameters

- For intubated patients with NUTRIC⁴⁷ score =5 with severe malnutrition per clinical assessment, unless contraindicated (see below) enteral access should be obtained and tube feeds initiated within 48 hours of admission
- For non-intubated severely malnourished patients or patients with NUTRIC score =5 who remain NPO or on a clear liquid diet on ICU day 5, get enteral access and initiate feeds unless contraindicated (see below)
- After resuscitation is complete (as defined by the resuscitation protocol), start tube feeds at 20 mL/hour and if no moderate or severe intolerances exist, advance by 10 mL/hour every 4-6 hours until the targeted goal is reached
- If post-pyloric enteral access is unavailable after multiple attempts, gastric feeds via a nasogastric tube may be initiated with aspiration precautions and gastric residual volume checks every 4 hours, tube feeds should only be held for residuals >500 mL or other signs of intolerance (e.g. emesis, distension)
- Enteral feeds should be no greater than 10ml/hour for the following high vasopressor requirements:
 - Norepinephrine or Epinephrine >0.1mcg/kg/min
 - Phenylephrine >1mcg/kg/min
 - Dopamine >10mcg/kg/min
 - Multiple vasopressors

Contraindications for tube feeds (risk for non-occlusive bowel necrosis)

- Active shock resuscitation
- Mean arterial pressure <60 mmHg for >60 minutes
- Acute respiratory distress syndrome with prone position
- Moderate or severe distention for >48 hours on an elemental diet
- Ischemic heart disease requiring vasopressors
- Bladder pressure >20 mmHg
- Vasopressin use
- Paralytic use

Tube feed formula	Kcal/mL	Protein g/L
Immune enhancing	1.5	94
Polymeric	1.5	63
Semi-elemental	1.2	75
Additives	Kcal/pack	Contents/pack
Juven®	80	7g glutamine, 7g arginine
Benefiber®	15	3g soluble fiber
Protein liquid	60	15g protein
<p>Indications for immune enhancing formula (administer for 10 days following surgery or trauma)</p> <ol style="list-style-type: none"> Non-trauma patients <ul style="list-style-type: none"> Moderately or severely malnourished patients undergoing major gastrointestinal surgery should receive immune enhancing formulas for 5-7 day preoperatively and 10 days postoperatively Trauma patients <ul style="list-style-type: none"> Major torso trauma <ul style="list-style-type: none"> Combined flail chest/pulmonary contusion anticipated to require prolonged mechanical ventilation Thoracotomy with lung resection, aortic repair, or diaphragm repair Patients >45 years old with 4 or more rib fractures or flail chest Major abdominal trauma Two or more of the following: <ul style="list-style-type: none"> >6 unit transfusion requirement Major pelvic fracture (acetabular, vertical shear, open book) Two or more long bone fractures 		
<p>Indications for polymeric formula</p> <ul style="list-style-type: none"> Patients who do not meet the criteria for immune enhancing formula but have normal digestive and absorptive capacity of the gastrointestinal tract Patients who have received 10 days of immune enhancing formula administration 		

Indications for semi-elemental formula

- Pancreatitis
- Intolerance to the first formula used
- Short gut syndrome
- High output distal colonic or ileal fistula
- Persistent, severe diarrhea for >48 hours on polymeric formula

Indications for Juven®*

- After intraoperative ischemia/reperfusion injury (systolic blood pressure <90 mmHg for >1 hour or serum lactate >4 mmol/L)
- After cardiac arrest or burn injury
- Thoracoabdominal radiation and/or chemotherapy
- Major torso trauma with Injury Severity Score >17
- Post-operative patients at high risk for poor wound healing
- Prolonged mechanical ventilation

*Do not use Juven® if the patient is status post solid organ transplantation

Indications for total parenteral nutrition

- Massive small bowel resection refractory to enteral feeds
- High output fistula after failure of elemental diet
- Unable to meet >60% caloric and protein goals enterally by ICU day 7
- Unable to meet >85% caloric and protein goals enterally by ICU day 10
- High risk for non-occlusive bowel necrosis after ICU day 7

- TPN may be considered earlier in patients with severe malnutrition or NUTRIC =5 and contraindications to enteral nutrition feeding

- Lipids should not be given to critically ill patients who require parenteral nutrition during their first week of hospitalization

Weekly indirect calorimetry assessments

- For mechanically ventilated patients with FiO₂ <60%, PEEP <10 mmHg, no leaky chest tubes or leaky endotracheal tubes, bronchopleural fistula, or renal replacement therapy within 12 hours and are receiving enteral or parenteral nutrition at goal rate

- Measure 24-hour urine urea nitrogen weekly for patients who are not receiving renal replacement therapy or diuresis


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

NPO: nothing by mouth, ICU: intensive care unit, FiO2: fraction of inspired oxygen, PEEP: positive end-expiratory pressure

For peer review only

Daily Wake Up Plus BEST (Breathing to Extubate Spontaneous Trial)

(To occur for endotracheally intubated patients: 4E/4W between 0330-0430; MICU between 0800-0930)



Do not file in Medical Record after Discharge

Patient Name:

Patient Identification #:

